DALE MICHAEL D - 17 Feb 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
SENIOR VICE PRESIDENT
Signature
/s/ Michael D. Dale by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
17 Feb 2023
Transactions value $
$0
Form type
4
Filing time
22 Feb 2023, 17:46:04 UTC
Previous filing
10 Mar 2022
Next filing
02 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +9,504 +22.75% $0 51,284 17 Feb 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +37,483 $0 37,483 17 Feb 2023 Common Shares 37,483 $106.24 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,494 on February 17, 2024, 12,494 on February 17, 2025, and 12,495 on February 17, 2026.